Peer-Reviewed Results of Bangladesh Medical College Prospective Study: Ivermectin & Doxycycline Combination Effectively Treats Mild to Moderate COVID-19
SEP 23, 2020
BANGLADESH MEDICAL COLLEGE, COVID-19,
DOXYCYCLINE, IVERMECTIN,
The Journal of Bangladesh College of Physicians and Surgeons
accepted the first case series study authored by Dr. Tarek Alam working with the Bangladesh Medical College.
TrialSite showcased these results after an interview with Dr. Alam.
Titled “A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline,”
the peer-reviewed conclusion
suggests the combination of ivermectin and doxycycline is very effective in viral clearance of mild to moderately sick COVID-19 patients.The findings from this important medical journal in Bangladesh,
Study Results
In this hospital approved protocol, a prospective study combining ivermectin and doxycycline for treating mild to moderately ill patients infected with SARS-CoV-2,100 patients infected with COVID-19 were enrolled with a predefined inclusion and exclusion criteria.
The study included 64 males and 36 females respectively aging from 8 to 84.
After administration of the off label combination therapy, all patients tested negative and their symptoms demonstrated marked improvement within 72 hours.
The study team identified no noticeable side effects.
The study team
concluded in this peer-reviewed report that ivermectin and doxycycline were “found to be very effective in viral clearance in mild and moderately sick COVID-19 patients.”
Randomized Trial Moves Forward As mentioned previously, Dr. Alam informed TrialSite that the authorities in Bangladesh have approved the randomized controlled trial based on the efforts of his work to date.
TrialSite reported that Dr. Alam was first planning this study to further investigate “the People’s Medicine” back in July.
the world 8th most populated nation, are not trivial nor remote.
Rather, they reflect a growing real-world evidence that national research agencies, including the National Institutes of Health in the United States,
should undertake larger multicenter studies to validate and recommend this combination therapy to include in national COVID-19 guidelines.
Called “The People’s Medicine” in Bangladesh, the time is now for formalized study in the United States.
As COVID-19 continues to wreak havoc around the world—as of this writing, 31 million reported cases worldwide with nearly 1 million deaths (200,000 in America alone)—health, economies, and civil societies feel the growing strain.
Cost effective and widely available treatments must be found to economically and expeditiously address and contain this contagion.
A study of ivermectin isn’t a replacement for the mission-critical vaccines (Moderna, Pfizer, etc.) and powerful monoclonal antibodies under development by Regeneron, Eli Lilly and others.
Rather, they all complement another as a range of therapies at different price points are required to take on COVID-19 for the long run